Coronavirus | West Bengal likely to lose chance to conduct Phase II trial of Sputnik V for want of govt. approval

 thehindu.com  11/22/2020 11:19:50 

West Bengal will likely lose the chance to conduct Phase II clinical trial of Russian COVID-19 vaccine candidate Sputnik V because of the delay in grant of approval by the State government, a top official of an organisation involved in facilitating the exercise said on Sunday.

The trials were proposed to start at the State-run College of Medicine and Sagore Dutta Hospital (CMSDH) in North 24 Parganas district adjoining Kolkata later this week along with six other centres in different parts of the country.

We are on the verge of losing Phase II trials of Sputnik V vaccine at the CMSDH because of the slow approach of the State Health Department in giving the approval. We had applied for the approval on November 4 and there is no response yet, the head of business development at site management organisation CliniMed LifeSciences, Snehendu Koner, told PTI.

He said while the initial feasibility process at CMSDH started along with the other centres where the trials are to take place, the approval could not be obtained in time.

After securing the Health Departments approval, the consent of the hospitals Institutional Ethics Committee (IEC) is also required before starting the trials, Mr. Koner said.

The IECs of the other six institutions have already given the go-ahead for the trials.

When contacted, a senior official of the State Health Department, who was unwilling to be named, said, This is an internal matter of our department. However, I believe that several official holidays on account of festivals could have delayed the approval process. I cannot talk much about it. We will look into it.

The site management organisation had conducted necessary surveys to check infrastructure and cold storage facilities at the Sagore Dutta Hospital before approaching the state health department for approval to conduct the trials.

Such approvals from the State Health Department are not required to conduct trials for any vaccines or drugs. But surprisingly, we were asked to seek approval this time which delayed the process and eventually we are losing it, he said.

Clinical trials of Sputnik V will be conducted by pharma major Dr. Reddys Laboratories in coordination with Russian Direct Investment Fund (RDIF).

The RDIF will be supplying 100 million doses of its potential COVID-19 vaccine to Dr. Reddys Lab.

During the Phase II trials, 100 volunteers will be chosen all over the country. Out of them 75 will be administered the vaccine, while the rest will be given placebo  a substance or treatment which is designed to have no therapeutic value.

Mr. Koner said Phase III of the trial of the vaccine candidate will begin in India in January and the state health department and the CMSDH will be urged to expedite the approval process.

The site management organisation facilitates clinical trials by national and global pharmaceutical companies engaged in drug and vaccine development.

Citing interim trial results, Russias Health Ministry claimed earlier this month that Sputnik V vaccine had shown 92% efficacy in preventing COVID-19.

The announcement had followed results unveiled earlier by vaccine developers Pfizer and BioNTech, who said their vaccine was more than 90% effective at preventing the coronavirus disease.

The calculation was based on 20 confirmed COVID-19 cases split between vaccinated individuals and those who received the placebo, the RDIF had said.

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. Its a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

« Go back